Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanjin tablets are a traditional Chinese patent medicine used primarily for the treatment of acute uncomplicated lower urinary tract infections (UTIs), especially those presenting with symptoms such as dysuria, urinary urgency, frequency, and suprapubic pain. The formulation consists of five herbal ingredients—Rosae Laevigatae Radix, Smilacis Chinae Rhizoma, Melastomae Normalis Radix, Lygodii Herba, and Centellae Herba. Chemical profiling has identified over 190 compounds in the product; several have demonstrated antimicrobial and anti-inflammatory activities relevant to UTI management. Mechanistically, network pharmacology studies suggest that multiple active compounds in Sanjin tablets interact with a range of targets involved in infection and inflammation pathways. The drug is typically administered orally as film- or sugar-coated tablets[2][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanjin tablets.